StreetInsider.com News Articles

Regeneron Pharma (REGN) Reiterated at Overweight by Cantor Fitzgerald

Mon, 13 Jul 2026 07:41:05 -0400

Cantor Fitzgerald analyst Carter Gould reiterated an Overweight rating and $750.00 price target on Regeneron Pharma (NASDAQ: REGN).

The analyst commented, "In discussing REGN’s pozelimab/cemdisiran, the KOL called out the limited use of systemic therapies currently by retinal specialists, and acknowledged their introduction would likely face some initial obstacles. Nevertheless, he saw this as surmountable given the clinical unmet need, and if supported by robust data. The KOL offered cautious optimism that the REGN dual-pronged systemic approach could drive greater complement suppression than that seen with existing approved options. If so, he felt this had a good chance of translating to

Regeneron Pharma (REGN) PT Lowered to $854 at Piper Sandler

Thu, 09 Jul 2026 07:11:23 -0400

Piper Sandler analyst Biren Amin lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $854.00 (from $855.00) while maintaining a Overweight rating.

Regeneron Pharma (REGN) PT Lowered to $730 at Morgan Stanley

Wed, 08 Jul 2026 08:08:50 -0400

Morgan Stanley analyst Matthew Harrison lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $730.00 (from $788.00) while maintaining a Equalweight rating.

Form 4 REGENERON PHARMACEUTICAL For: Jul 02 Filed by: RYAN ARTHUR F

Tue, 07 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26741788.html

Form 4 REGENERON PHARMACEUTICAL For: Jul 02 Filed by: RYAN ARTHUR F

Tue, 07 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260707/26741788.html

Regeneron Pharma (REGN) PT Lowered to $696 at RBC Capital

Tue, 07 Jul 2026 07:55:40 -0400

RBC Capital analyst Brian Abrahams lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $696.00 (from $707.00) while maintaining a Sector Perform rating.

Regeneron Pharma (REGN) PT Lowered to $769 at Truist Securities

Tue, 07 Jul 2026 07:09:38 -0400

Truist Securities analyst Greg Renza lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $769.00 (from $778.00) while maintaining a Buy rating.

Form 8-K REGENERON PHARMACEUTICAL For: Jul 06

Mon, 06 Jul 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260706/26732567.html

Form 8-K REGENERON PHARMACEUTICAL For: Jul 06

Mon, 06 Jul 2026 07:01:00 -0400

si-local-file:///var/storage/secattach/20260706/26732567.html

Regeneron Pharma (REGN) PT Lowered to $750 at Cantor Fitzgerald on Negative Eylea Optics

Mon, 06 Jul 2026 06:46:32 -0400

Cantor Fitzgerald analyst Carter Gould lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $750.00 (from $785.00) while maintaining an Overweight rating.

The analyst commented, "Anticipate a lot of crosscurrents. We expect negative optics around Eylea HD/SD and Dupixent misses vs. consensus, as well as a lack of clarity around Eylea HD PFS messaging. At the same time, we still see upside on Sanofi Collaboration revenue and EPS. Those dynamics and valuation support may mitigate some of the pressure, but investors want tangible evidence of late-stage clinical wins and progress. With that in mind, we expect a focus on the

Regeneron Pharma (REGN) PT Lowered to $750 at Cantor Fitzgerald on Negative Eylea Optics

Mon, 06 Jul 2026 06:46:32 -0400

Cantor Fitzgerald analyst Carter Gould lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $750.00 (from $785.00) while maintaining an Overweight rating.

Regeneron Pharma (REGN) PT Lowered to $800 at HSBC

Mon, 06 Jul 2026 01:35:29 -0400

HSBC analyst Rajesh Kumar lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $800.00 (from $990.00) while maintaining a Buy rating.

Form 144 REGENERON PHARMACEUTICAL Filed by: RYAN ARTHUR F

Thu, 02 Jul 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260702/26729761.html

Form 144 REGENERON PHARMACEUTICAL Filed by: RYAN ARTHUR F

Thu, 02 Jul 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20260702/26729761.html

FDA selects 7 companies for domestic drug manufacturing pilot

Mon, 29 Jun 2026 16:20:42 -0400

The U.S. Food and Drug Administration has selected seven companies to participate in its PreCheck Pilot Program, an initiative aimed at supporting the development of new domestic pharmaceutical manufacturing facilities.

The FDA launched the program on February 1, 2026, following Executive Order 14293 signed by President Trump in May 2025. Between February 1 and March 1, 2026, the agency received more than 80 requests to participate. FDA drug and biologic experts evaluated all requests using a scoring framework that considered products to be manufactured, stage of facility development, anticipated timelines, and manufacturing innovation.